1 / 21

Intel Gen x Technologies, Corp.

Intel Gen x Technologies, Corp. We make approved drugs better. November 2007. Who we are. Technologies. Oral Film. Partnerships. Schwarz Pharma Azur Pharma Cannasat Therapeutics Cary Pharmaceuticals . Versatab Layered Tablets. Patents. 10 drugs Large Markets.

kimn
Télécharger la présentation

Intel Gen x Technologies, Corp.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IntelGenxTechnologies, Corp. We make approved drugs better November 2007

  2. Who we are Technologies Oral Film Partnerships Schwarz Pharma Azur Pharma Cannasat Therapeutics Cary Pharmaceuticals Versatab Layered Tablets Patents 10 drugsLarge Markets Addressing unmet needs: • Erectile Dysfunction US$2b • Osteoarthritis – US$10b • Neuropathic Pain – US$10b • Depression – US$15b • Smoking Cessation – US$1b 3 issued, 7 pending

  3. Who Are We - Financial Overview We make approved drugs better • Founded: 2003 • Listed July 2006 • OTCBB: IGXT • Recent price: $1.75 • Share Volume (avg): 50k/day • Cash/Equivalent: $1m • Debt – Long-term: None • Burn rate (qtrly): ~$300k • Market Capitalization: ~$30m • Shares fully diluted: 17m • Insider ownership: 67%

  4. Management Team Horst G. Zerbe, Ph.D., CEO holds 40 patents, 27 yrs of industry experience with Schwarz Pharma, 3M Pharmaceutical, as VP of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ, and most recently as president of Smartrix Technologies Inc. Gino Di Iorio, CA, CFO Extensive experience in financial analysis, accounting, and regulatory filings. Prior companies include Viropro Inc., Draft inc., Sitel Corp. James Wittenberg, R.Ph, MS, Vice President, Bus. Dev. >20 years of experience in the pharmaceutical industry in market research and business development, most recently as Director of Business Development at Schwarz Pharma and Boots.

  5. Pharmaceutical Industry Facing Challenges Fewer new drugs coming to market Increase in Generics Market share of generics and % growth Number of New Drugs Approved in the U.S. Source: FDA Pharmaceutical Industry US$650b growing at 5-7% Industry growth slowing because of increased generics and fewer product launches Source: IMS

  6. Drug Delivery Industry Growing Faster Than Rest Of Industry Drug Delivery Industry US$60b growing at 15% Controlled release drugs, improved drugs or “Ultra drugs” to extend product life cycle of successful branded drugs after patent expiration using 505(b)(2) approach Source: IMS

  7. IntelGenx - Product Pipeline Preclinical Development Pilot BE Study Mfg. Scale-Up Pivotal BE Study Commercial Launch Platform Prenatal Vitamin Antidepressant Osteoarthritis Smoking Cessation Neuropathic Pain Antihypertensive Antihypertensive Erectile Dysfunction Tablet Tablet Tablet Tablet Tablet Tablet Tablet Oral Film n/a H1/08 H2/08 H1/10 H1/10 H2/09 H2/09 H2/10 H2/10 Partnered drugs

  8. Oral Film Market – New Opportunities • Huge success in OTC products • Anti-histamines • Anti-flatulence • Anti-diarrhea • Anti-emesis • Cough/cold products • Advantages of Oral Film products • Reduce problems in swallowing • Instant release of drugs • Lower dose of drug required • Targeting children and elderly patients • Patient compliance

  9. Quick Release Oral Strips Advantages • Instant release of drugs • Avoids hepatic inactivation (first-pass effect) • FDA approved for pharmaceutical products • Improved patient compliance • Adjustable flavours and textures • Patented technology Onset of action and plasma concentration after administration of wafer and conventional tablet

  10. Oral Strips – Erectile Dysfunction Indication: Erectile Dysfunction 2006 global sales (US$): $2.0b Partner: Internal project Current status: Formulation development ongoing Expected commercialization: 2009 Patent Status: Expiry 2023 Rationale • User friendly • Easier to take • Rapid onset of action

  11. Versatab Multilayer Tablet Platform Advantages • High drug loading capacity (important for once-daily formulations) • Ability to co-release multiple drugs with different release rates • Suitable for large number of actives • Highly versatile, broad range of delivery profiles • Manufacturing cost savings of 50% compared to other oral delivery technologies Erodible Cover Active Matrix Erodible Cover

  12. Versatab Multi-Layered Tablets – NovelAntidepressant Indication: Severe Depressive Disorder 2006 global sales (US$): > $1 b Partner: Joint Venture with Cary Pharma Current status: Pilot Phase I Study Completed Expected commercialization: 2009 Patent Status: US application under review Rationale • Uniquely positioned for target indication Source: Company reports

  13. Need for Combination Products +15% 2006-2010 Combination drugs taking a leadership role to create a strategic advantage against generics Source: IMS

  14. Versatab Multi-Layered Tablets – Bupropion HCL + Mecamylamine HCL Indication: Smoking Cessation 2006 global sales (US$): > $1 b Partner: Cary Pharma Current status: Phase I ongoing Expected commercialization: 2009 Patent Status: US application pending, use patent issued Rationale • May have fewer side effects • Dual mechanism of action Source: Company reports

  15. Versatab Multi-Layered Tablets – INT005/05 Status: Active drugs: NSAID + Gastroprotectant Platform: Multilayer Tablet Indication: Osteoarthritis 2005 global sales (US$): 12 bn total OA market 2006 projected: 500 million Partner: US Company S. Current status: Formulation development completed Expected commercialization: 2009 Patent Status: US and PCT applications pending • Total OA market > US$12 bn • Growing at +12% • Strong growth due to withdrawal of COX-2 inhibitors

  16. Versatab Multi-Layered Tablets – MetropololSuccinate Indication: Hypertension 2006 global sales (US$): $1.7b Partner: Internal project Current status: Manufacturing Scale-up ongoing Expected commercialization: 2008 Patent Status: US application pending Rationale • Lower cost alternative to branded drug Source: Company reports

  17. Versatab- In Vivo Performance Plasma concentrations of Metoprolol Succinate IntelGenx trilayer tablets vs Toprol XL tablets (single dose, fasted, n=6)

  18. Competitive Landscape – Drug Delivery

  19. Revenue Projection

  20. IntelGenx - Delivering Value Reasons to Invest • Strong management and key scientific expertise • Broad product pipeline – 10 drugs addressing a total US$20 billion markets • Unique, proprietary drug delivery platform technologies • Multiple Partnerships - 4 drugs in development • Clinical Development in progress for 4 products • Near-term revenue expectations - Prenatal Vitamin • Attractive valuation

  21. Thank You IntelGenxTechnologies, Corp. IntelGenx Thanks you very much for your time and attention. November 2007

More Related